Form 4 holding
Director
Cibus, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 14,916,640
- Estimated value
- $22,374,960
- Report date
- 29 Jan 2026
- Price
- $1.50
- Ownership
- Direct
Rory B. Riggs
Insider Reports History
- Reporting-owner location
- Ridgefield, NJ
- Latest reporting-owner signature
-
Jason Stokes, Attorney-in-Fact for Rory B. Riggs
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Rory B. Riggs
Form 4 holding
Director
Royalty Pharma plc
- Security class
- Class A Ordinary Shares
- Shares / value
- 320,099
- Estimated value
- $8,817,959
- Report date
- 20 Feb 2024
- Price
- $27.55
- Ownership
- Direct
Form 4 holding
Director
Royalty Pharma plc
- Security class
- Class A Ordinary Shares
- Shares / value
- 85,187
- Estimated value
- $2,346,697
- Report date
- 20 Feb 2024
- Price
- $27.55
- Ownership
- By New Ventures III LLC
Form 4 holding
Director
FIBROGEN INC
- Security class
- Common Stock
- Shares / value
- 605,713
- Estimated value
- $460,342
- Report date
- 26 May 2021
- Price
- $0.7600
- Ownership
- Indirect
Form 4 holding
Director
Royalty Pharma plc
- Security class
- Class A Ordinary Shares
- Shares / value
- 15,000
- Estimated value
- $413,214
- Report date
- 20 Feb 2024
- Price
- $27.55
- Ownership
- By Spouse
Form 4 holding
Director
FIBROGEN INC
- Security class
- Common Stock
- Shares / value
- 395,750
- Estimated value
- $300,770
- Report date
- 26 May 2021
- Price
- $0.7600
- Ownership
- Direct
Form 4 holding
Director
Cibus, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 23,807
- Estimated value
- $41,424
- Report date
- 29 Jan 2026
- Price
- $1.74
- Ownership
- Indirect
Form 4 holding
Director
Cibus, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 20,974
- Estimated value
- $36,494
- Report date
- 29 Jan 2026
- Price
- $1.74
- Ownership
- By Spouse
Form 4 holding
Director
Intra-Cellular Therapies, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 02 Apr 2025
- Price
- $132.00
- Ownership
- Direct
Form 4 holding
Director
Intra-Cellular Therapies, Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 02 Apr 2025
- Price
- $132.00
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Royalty Pharma plc
- Security class
- LP interests in RPI US Partners 2019, LP
- Shares / value
- 270,000
- Estimated value
- Report date
- 20 Feb 2024
- Price
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
Form 4 holding
Director
Cibus, Inc.
- Security class
- Stock Option (Right-to-Buy)
- Shares / value
- 77,586
- Estimated value
- Report date
- 02 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
Form 4 holding
Director
FIBROGEN INC
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 7,800
- Estimated value
- Report date
- 26 May 2021
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Cibus, Inc.
- Security class
- Pre-Funded Warrant (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 09 Jun 2025
- Price
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
Form 4 holding
Director
Intra-Cellular Therapies, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 02 Apr 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Rory B. Riggs
4
CBUS
Cibus, Inc.
- Report period
- 02 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Jun 2026, 17:43
- Role
- Director
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 29 Jan 2026
- Transactions
- 1
- Transaction value
- +$500,000
- Accepted by SEC
- 02 Feb 2026, 20:27
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 09 Jun 2025
- Transactions
- 4
- Transaction value
- +$900
- Accepted by SEC
- 11 Jun 2025, 17:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 05 Jun 2025
- Transactions
- 1
- Transaction value
- +$10,000,000
- Accepted by SEC
- 10 Jun 2025, 16:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 22 May 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 27 May 2025, 15:07
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 02 Apr 2025
- Transactions
- 9
- Transaction value
- -$17,359,584
- Accepted by SEC
- 02 Apr 2025, 17:47
- Role
- Director
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 21 Jan 2025
- Transactions
- 2
- Transaction value
- +$9,999,600
- Accepted by SEC
- 23 Jan 2025, 16:19
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 31 Dec 2024
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 10 Jan 2025, 09:51
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 31 Dec 2024
- Transactions
- 1
- Transaction value
- +$17,957
- Accepted by SEC
- 03 Jan 2025, 18:01
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 30 Sep 2024
- Transactions
- 1
- Transaction value
- +$18,000
- Accepted by SEC
- 02 Oct 2024, 18:01
- Role
- Director
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 18 Sep 2024
- Transactions
- 1
- Transaction value
- +$1,000,000
- Accepted by SEC
- 20 Sep 2024, 17:48
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 28 Jun 2024
- Transactions
- 1
- Transaction value
- +$17,944
- Accepted by SEC
- 02 Jul 2024, 20:00
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 23 Jun 2024
- Transactions
- 5
- Transaction value
- +$6.66
- Accepted by SEC
- 25 Jun 2024, 18:04
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 14 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2024, 18:02
- Role
- Director
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 11 Jun 2024
- Transactions
- 2
- Transaction value
- +$1,000,008
- Accepted by SEC
- 14 Jun 2024, 06:53
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 31 Mar 2024
- Transactions
- 1
- Transaction value
- +$17,992
- Accepted by SEC
- 02 Apr 2024, 16:15
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 20 Mar 2024
- Transactions
- 2
- Transaction value
- +$371,200
- Accepted by SEC
- 22 Mar 2024, 16:12
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 20 Feb 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 22 Feb 2024, 19:23
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 02 Jan 2024
- Transactions
- 3
- Transaction value
- -$13,222,862
- Accepted by SEC
- 04 Jan 2024, 17:16
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 31 Dec 2023
- Transactions
- 1
- Transaction value
- +$17,977
- Accepted by SEC
- 03 Jan 2024, 18:46
- Role
- Director
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 29 Dec 2023
- Transactions
- 5
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2024, 19:08
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
CBUS
Cibus, Inc.
- Report period
- 12 Dec 2023
- Transactions
- 3
- Transaction value
- +$5,999,492
- Accepted by SEC
- 14 Dec 2023, 17:10
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 13 Nov 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Nov 2023, 17:17
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 30 Sep 2023
- Transactions
- 1
- Transaction value
- +$17,971
- Accepted by SEC
- 02 Oct 2023, 17:29
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 08 Aug 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 08 Aug 2023, 17:39
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 30 Jun 2023
- Transactions
- 1
- Transaction value
- +$17,666
- Accepted by SEC
- 05 Jul 2023, 16:30
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 23 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2023, 17:11
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 23 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 26 Jun 2023, 16:14
- Role
- Director
- Next action
- Open filing details
4/A
CBUS
Cibus, Inc.
- Report period
- 31 May 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2023, 16:05
- Role
- Chief Executive Officer, Director, 10%+ Owner
- Next action
- Open filing details
3
CBUS
Cibus, Inc.
- Report period
- 31 May 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2023, 07:00
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 22 May 2023
- Transactions
- 1
- Transaction value
- -$57,435,000
- Accepted by SEC
- 22 May 2023, 20:36
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 09 May 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 May 2023, 18:43
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 31 Mar 2023
- Transactions
- 1
- Transaction value
- +$16,949
- Accepted by SEC
- 04 Apr 2023, 17:01
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 29 Mar 2023
- Transactions
- 2
- Transaction value
- -$5,081,111
- Accepted by SEC
- 30 Mar 2023, 17:53
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 17 Feb 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 17 Feb 2023, 15:59
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 30 Dec 2022
- Transactions
- 1
- Transaction value
- +$16,987
- Accepted by SEC
- 03 Jan 2023, 15:18
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 09 Dec 2022
- Transactions
- 2
- Transaction value
- -$2,520,623
- Accepted by SEC
- 13 Dec 2022, 17:20
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 17 Nov 2022
- Transactions
- 1
- Transaction value
- -$5,079,924
- Accepted by SEC
- 21 Nov 2022, 17:12
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 30 Sep 2022
- Transactions
- 1
- Transaction value
- +$16,983
- Accepted by SEC
- 04 Oct 2022, 16:11
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 14 Sep 2022
- Transactions
- 2
- Transaction value
- -$4,230,387
- Accepted by SEC
- 15 Sep 2022, 19:56
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 09 Aug 2022
- Transactions
- 1
- Transaction value
- -$1,967,823
- Accepted by SEC
- 11 Aug 2022, 17:07
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 30 Jun 2022
- Transactions
- 1
- Transaction value
- +$16,496
- Accepted by SEC
- 05 Jul 2022, 16:06
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 29 Jun 2022
- Transactions
- 1
- Transaction value
- -$1,265,238
- Accepted by SEC
- 29 Jun 2022, 18:02
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 09 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2022, 17:08
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 19 May 2022
- Transactions
- 2
- Transaction value
- -$5,913,306
- Accepted by SEC
- 23 May 2022, 16:55
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 31 Mar 2022
- Transactions
- 1
- Transaction value
- +$15,726
- Accepted by SEC
- 04 Apr 2022, 16:08
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 29 Mar 2022
- Transactions
- 1
- Transaction value
- -$2,315,322
- Accepted by SEC
- 30 Mar 2022, 18:46
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 17 Mar 2022
- Transactions
- 10
- Transaction value
- -$6,667,521
- Accepted by SEC
- 21 Mar 2022, 18:20
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 16 Mar 2022
- Transactions
- 6
- Transaction value
- -$13,623,979
- Accepted by SEC
- 18 Mar 2022, 20:12
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 31 Dec 2021
- Transactions
- 1
- Transaction value
- +$15,702
- Accepted by SEC
- 04 Jan 2022, 20:50
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 28 Dec 2021
- Transactions
- 9
- Transaction value
- -$7,400,767
- Accepted by SEC
- 30 Dec 2021, 17:07
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 16 Nov 2021
- Transactions
- 10
- Transaction value
- -$9,076,492
- Accepted by SEC
- 18 Nov 2021, 18:15
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 30 Sep 2021
- Transactions
- 1
- Transaction value
- +$15,732
- Accepted by SEC
- 04 Oct 2021, 16:24
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 28 Sep 2021
- Transactions
- 12
- Transaction value
- -$4,688,288
- Accepted by SEC
- 30 Sep 2021, 15:56
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 30 Jun 2021
- Transactions
- 1
- Transaction value
- +$15,716
- Accepted by SEC
- 02 Jul 2021, 16:52
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 25 Jun 2021
- Transactions
- 5
- Transaction value
- -$55,370,134
- Accepted by SEC
- 29 Jun 2021, 20:31
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 21 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 22 Jun 2021, 16:21
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 07 Jun 2021
- Transactions
- 1
- Transaction value
- +$12,385,399
- Accepted by SEC
- 08 Jun 2021, 20:13
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 27 May 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Jun 2021, 16:05
- Role
- Director
- Next action
- Open filing details
4
FGEN
FIBROGEN INC
- Report period
- 26 May 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 28 May 2021, 19:08
- Role
- Director
- Next action
- Open filing details
4
RPRX
Royalty Pharma plc
- Report period
- 07 May 2021
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 11 May 2021, 21:00
- Role
- Director
- Next action
- Open filing details
4
ITCI
Intra-Cellular Therapies, Inc.
- Report period
- 18 Jun 2019
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 15 Oct 2024, 18:00
- Role
- Director
- Next action
- Open filing details